

IAG933

YAP/TAZ-TEAD


YAP/TAZ-TEAD PPI inhibitor

Ph. I for mesothelioma

from virtual screening, SBDD, and property-based opt.

Nat. Cancer, April 2024

NOVARTIS BIOMEDICAL RESEARCH, BASEL, CH



HRO761

WRN helicase


WRN helicase allosteric inhibitor

Ph. I for MSI-high solid tumors

from HTS, SBDD, and lipE-guided opt.

Nature, April 2024

NOVARTIS BIOMEDICAL RESEARCH, BASEL, CH



RMC-6236

pan-RAS(ON)


macrocyclic pan-RAS(ON) noncovalent inhibitor

Ph. I/II for RAS-mutated lung cancers

structure-guided design from the natural product, sanglifehrin A

Cancer Discov., April 2024

REVOLUTION MEDICINES, REDWOOD CITY, CA



tavapadon

D₁/D₅ receptors


D₁/D₅ receptors partial agonist

Ph. III for Parkinson's disease

from HTS and SAR opt

Press Release, April 2024

Pfizer, NY / CERVEL THERAPEUTICS, MA



KT-333

STAT3


VHL-based STAT3 degrader

Ph. I for lymphoma, leukemia, solid tumors

from known inhibitors

Press Release, April 2024

KYMERA THERAPEUTICS, WATERTOWN, MA



TNG908

PRMT5


brain-penetrant PRMT5:MTA complex inhibitor

Ph. I/II for solid tumors

HTS, LBDD, and SBDD

J. Med. Chem., April 2024

TANGO THERAPEUTICS, BOSTON, MA



NST-628

RAF-MEK


brain-penetrant (pan-RAF)-MEK molecular glue

Ph. I for solid tumors

deliberate opt. of dual phospho-MEK/ERK inhibition, CNS penetration, and ADME/DMPK

Cancer Discov., April 2024

NESTED THERAPEUTICS, CAMBRIDGE, MA



CVN293

KCNK13


brain-penetrant KCNK13 inhibitor

preclinical for neurodegenerative disorders

from HTS, metabolic stab., and PK opt

ACS Med. Chem. Lett., April 2024

CEREVANCE LIMITED, CAMBRIDGE, UK



BDTX-1535

EGFR


brain-penetrant EGFR "MasterKey" inhibitor

Ph. I/II for glioma, glioblastoma, lung cancer

hit identification method undisclosed

Press Release, April 2024

BLACK DIAMOND THERAPEUTICS, CAMBRIDGE, MA



sovleplenib

Syk

Syk inhibitor

Ph. III for autoimmune hemolytic anemia, primary immune thrombocytopenia

from internal library screening, SAR, and PK opt.

ACS Med. Chem. Lett., April 2024

HUTCHMED LIMITED, SHANGHAI, CN